Coastlands Capital LP purchased $53K of KTTA (indirect holdings)
Coastlands Capital LP purchased 100,000 indirectly-held shares of Pasithea Therapeutics Corp. (KTTA) at $0.53 on 2026-06-17.
How this was made
The 30-second read
Why it matters
Coastlands Capital LP (10% owner) reported an indirect open-market purchase of 100,000 shares at $0.5300/share, with holdings after the trade of 3,835,035 shares.
Market read
Traders may treat the filing as a small bullish sentiment datapoint, but it lacks fundamental new information (no guidance/clinical/deal updates).
What to watch
No 10b5-1 plan and the filing is indirect; traders should avoid extrapolating to operational performance without corroborating catalysts (trial/data, financing, partnerships).
Background
The article is an SEC Form 4 insider transaction disclosure for Pasithea Therapeutics (KTTA).
Ticker impact
Pasithea Therapeutics (KTTA) disclosed a Form 4 showing Coastlands Capital LP bought 100,000 shares at $0.53 on 2026-06-17.
Likely limited near-term impact; any effect would be incremental sentiment rather than a re-rating catalyst.
Form 4 insider buying can support bullish sentiment, but the transaction size ($53k) is small and there’s no accompanying guidance, trial, or deal update in the filing.
Market effects
Minimal; this is company-specific ownership activity with no sector-wide regulatory/clinical signal.
None indicated.
None indicated.
Counterpoint
The purchase may reflect routine rebalancing or indirect holdings mechanics rather than a strong forward-looking view; small dollar value reduces signal strength.
Key entities
- issuerPasithea Therapeutics Corp.
Company whose shares were purchased; subject of the Form 4 disclosure (KTTA).
- 10% ownerCoastlands Capital LP
Reporter of the Form 4; executed an indirect open-market purchase on 2026-06-17.
- filingSEC Form 4
Primary-source insider transaction report filed 2026-06-22.
